HeartBeam Partners with Phoebe Putney Health System for First Pilot Study of Emergency Department Myocardial Infarction Software
March 02 2022 - 8:31AM
Business Wire
Business Associate Agreement and Clinical Trial
Agreement with Additional Planned Studies and Commercial and
Scientific Collaboration
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology for heart attack detection, today announced it has
signed a Business Associate Agreement (BAA) and Clinical Trial
Agreement (CTA) with Phoebe Putney Health System to conduct a pilot
study designed to evaluate HeartBeam’s Emergency Department (ED)
Myocardial Infarction (MI) software product.
Phoebe Putney Health System, headquartered in Albany, Georgia,
is a not-for-profit network of more than 4,500 physicians, nurses,
professional staff, and volunteers delivering compassionate,
high-quality healthcare to more than 500,000 residents in a
41-county region. HeartBeam will be partnering with Phoebe Putney
Emergency Department which serves over 100,000 patients
annually.
“Phoebe Putney’s Emergency Department is an ideal facility for
our first pilot study in a clinical setting for our ED MI software
product,” said Branislav Vajdic, PhD, Chief Executive Officer and
Founder of HeartBeam. “We look forward to working with the Phoebe
Putney team on this initial study, with plans for additional pilot
studies for our end-to-end prescription-only telehealth system for
remote heart attack detection in at risk patients. The agreement
also includes future scientific and commercial collaboration as
HeartBeam brings its products to market after FDA market
clearance.”
Doug Gregory, Vice President of Phoebe Heart and Vascular,
added, “We are excited to commence this study of EKGs done on
patients with chest pain previously treated in our emergency center
to help determine this technology’s effectiveness in rapidly
detecting a heart attack. Chest pain is the second most common
reason for an ED visit, with high costs associated with these
visits. HeartBeam’s software is a promising solution for more
accurate MI detection.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form S-1, which can
be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220302005187/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024